Communiqués Summit Therapeutics Inc.

Actions

SMMT

US86627T1088

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 18:03:33 28/08/2026			Varia. 5j.	Varia. 1 janv.
13,60 ^USD	-5,09 %		+3,80 %	-21,90 %

26/08	Les ETF en baisse, les contrats à terme sur actions mitigés avant l'ouverture mercredi suite à la publication des données sur l'inflation	MT
26/08	Les contrats à terme sur actions américaines stables avant l'ouverture, entre données d'inflation et attente des résultats de Nvidia	MT

Communiqués

26/08	Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China	BU
25/08	Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology	BU
13/08	Summit Therapeutics - Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer	AQ
12/08	Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer	BU
05/08	Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer	BU
27/07	Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026	AQ
23/07	Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026	BU
22/07	Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study	BU
16/07	Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026	BU
14/07	Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.	BU
09/06	Summit Therapeutics Announces Proposed Public Offering of Common Stock	BU
04/06	Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference	BU
31/05	Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non-small cell lung cancer: Overall survival results of the Phase 3 HARMONi-6 Slides	PU
31/05	Summit Therapeutics : Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China	PU
31/05	Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China	BU
30/05	A randomized, active-controlled phase 3 study of ivonescimab FOLFOX versus bevacizumab FOLFOX as first-line treatment of metastatic colorectal cancer: HARMONi-GI3	PU
30/05	Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026	BU
30/04	Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026	BU
27/03	Health-Related Quality of Life in Patients Previously Treated With an EGFR-TKI From HARMONi: A Phase 3 Trial of Ivonescimab vs Placebo Plus Chemotherapy	PU
27/03	Health-Related Quality of Life With Ivonescimab Versus Pembrolizumab for PD-L1 Positive, Non–Small Cell Lung Cancer (HARMONi-2): A Randomised, Double-Blind, Phase 3 Study in China	PU
27/03	Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026	BU
27/02	Summit Therapeutics to Present at Upcoming Investor Conferences	BU
23/02	Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025	BU
17/02	Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026	BU
30/01	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU